IDWeek 2016: Comorbidities Are Common and Rising Among People with HIV
- Details
- Category: HIV-Related Conditions
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
People living with HIV are increasingly experiencing a range of non-AIDS-related comorbidities as the population ages, including cardiovascular disease, kidney impairment, and bone loss leading to fractures, according to research presented at the recent IDWeek 2016 meeting in New Orleans.
Young Adolescents Need Only 2 Doses of Human Papillomavirus Vaccine, CDC Says
- Details
- Category: HPV Vaccines
- Published on Tuesday, 08 November 2016 00:00
- Written by Liz Highleyman
Adolescents age 11-14 years can receive 2 doses of the human papillomavirus (HPV) vaccine to prevent cancers caused by HPV, rather than the 3 doses previously recommended, according to the U.S. Centers for Disease Control and Prevention (CDC). This change is supported by a systematic review presented at the recent IDWeek meeting in New Orleans, which found that 2 vaccine doses were non-inferior to 3 doses for this age group.
IDWeek 2016: Tenofovir Alafenamide Works Well and Improves Kidney and Bone Markers in Older HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
A coformulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older individuals, and was associated with improvements in kidney function and bone density, which may be of greater concern for this group, according to a presentation last week at IDWeek 2106 in New Orleans.
IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 07 November 2016 00:00
- Written by Liz Highleyman
A new 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week course cured 99% of treatment-experienced patients, researchers reported at the recent IDWeek meeting in New Orleans. Response rates dropped off, however, when treatment was shortened to 6 weeks.
IDWeek 2016: Omega-3 Fatty Acids May Improve Triglycerides and Inflammation in HIV+ People
- Details
- Category: Approved HIV Drugs
- Published on Sunday, 06 November 2016 00:00
- Written by Liz Highleyman
Long-term use of omega-3 fatty acid supplements was associated with reduced levels of triglycerides and the inflammation biomarker C-reactive protein (CRP) in HIV-positive people with suppressed viral load, according to research presented last week at IDWeek 2016 in New Orleans.
More Articles...
- New Research Sheds Light on Origin of HIV in U.S., Dispelling Patient Zero Myth
- IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women
- IDWeek 2016: Do HIV-Positive Men with Undetectable Viral Load Need to Wear Condoms?
- IDWeek 2016: Ibalizumab Monoclonal Antibody Looks Promising for HIV Patients Left Behind
Web Design and Development by